Histone demethylase inhibitors
The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.
1. A compound having the structure of Formula 1:
wherein a compound of Formula 1 includes isomers and pharmaceutically acceptable salts thereof, and wherein:
n is 0 or 1;
R 4 is hydrogen or optionally substituted C 1 -C 6 alkyl;
R 6 is hydrogen or X—Y, wherein
X is a bond, O, S, N(R), C(O), N(R)C(O), C(O)N(R), or optionally substituted C 1 -C 3 alkyl, wherein
R is hydrogen or optionally substituted C 1 -C 6 alkyl, and
Y is optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and
R 5 , R 7 , and R 8 are each independently selected from hydrogen, halogen, hydroxyl, cyanyl, N(R 1 )(R 2 ), or optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkynyl, C 1 -C 6 alkenyl, C 1 -C 6 alkoxy, C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy or heteroaryl-S, wherein
R 1 is hydrogen or optionally substituted C 1 -C 6 alkyl, and
R 2 is optionally substituted alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkylalkyl, aryl-CO, heteroaryl-CO, cycloalkyl-CO, or alkyl-CO.
2. The compound of claim 1 , wherein n is 0 or 1, and R 4 is methyl.
3. A pharmaceutical composition comprising the compound of claim 1 .
4. A compound of Formula 2:
wherein a compound of Formula 2 includes isomers and pharmaceutically acceptable salts thereof, and wherein:
n is 0 or 1;
R 4 is hydrogen or optionally substituted C 1 -C 6 alkyl; and
R 3 is N(R)(R 9 ), N(R)C(O), C(O)N(R), or optionally substituted C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, C 1 -C 6 alkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy or heteroaryl-S, wherein
R is hydrogen or optionally substituted C 1 -C 6 alkyl, and
R 9 is optionally substituted C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 1 -C 6 alkoxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy or heteroaryl-S.
5. The compound of claim 4 , wherein n is 0 or 1.
6. The compound of claim 4 , wherein R 4 is hydrogen or methyl.
7. The compound of claim 4 , wherein R 3 is N(R)(R 9 ), and wherein R is methyl.
8. The compound of claim 7 , wherein R 9 is optionally substituted C 6 -C 10 aryl selected from optionally substituted halophenyl, alkylphenyl, haloalkylphenyl, halo(alkyloxy)phenyl, or haloalkyloxyphenyl.
9. The compound of claim 7 , wherein R 9 is optionally substituted chlorophenyl, difluorophenyl, chlorofluorophenyl, (trifluoroethyl)phenyl, (trifluoropropyl)-phenyl, methylphenyl (tolyl), dimethylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, (cyclopropylethyl)phenyl, cyclopropylphenyl, cyclobutylphenyl, cyclopentylphenyl, cyclohexylphenyl, (cyclobutylmethyl)phenyl, propoxyphenyl, (propylmethoxy)phenyl, (trifluoroethoxy)phenyl, (trifluoroethoxy)fluorophenyl, (trifluoroethoxy)dimethylphenyl, (propoxy)methylphenyl, (difluoromethoxy)methylphenyl, (quinolinyl)methylphenyl, (dihydroquinolinyl)methylphenyl, indolinylphenyl, dimethylaminophenyl, pyranylphenyl, methyldihydrobenzofuranyl, (indolinyl)methylphenyl, (pyrrolidinyl)methylphenyl, or thiole.
10. The compound of claim 4 , wherein R 3 is optionally substituted C 6 -C 10 aryl, selected from optionally substituted flurophenyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, cycloalkoxyphenyl, cycloalkoxymethylphenyl, or (cyclopropylmethoxy)methylphenyl.
11. The compound of claim 4 , wherein R 3 is optionally substituted C 6 -C 10 aryl-S, heterocyclyl, heteroaryl, or C 4 -C 12 carbocyclylalkoxy.
12. The compound of claim 4 , wherein R 3 is optionally substituted chlorophenyl, fluorophenyl, difluorophenyl, chlorofluorophenyl, (trifluoroethyl)phenyl, (trifluoropropyl)phenyl, methylphenyl (“tolyl”), dimethylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, cyclopropylphenyl, cyclobutylphenyl, cyclopentylphenyl, cyclohexylphenyl, (cyclopropylethyl)phenyl, (cyclobutylmethyl)phenyl, methoxyphenyl, ethoxyphenyl, propoxyphenyl, (cyclopropylmethoxy)phenyl, (trifluoroethoxy)phenyl, (methoxy)fluorophenyl, (trifluoroethoxy)fluorophenyl, (trifluoroethoxy)methylphenyl, (trifluoroethoxy)dimethylphenyl, (difluoromethoxy)methylphenyl, (propoxy)methylphenyl, (quinolinyl)methylphenyl, (dihydroquinolinyl)methylphenyl, (dihydroisoquinolinyl)methylphenyl, indolinylphenyl, dimethylaminophenyl, pyranylphenyl, methyldihydrobenzofuranyl, (indolinyl)methylphenyl, (pyrrolidinyl)methylphenyl, or thiole.
13. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a compound of claim 4 .
14. A compound having the structure of Formula 3:
wherein the compound of Formula 3 includes isomers and pharmaceutically acceptable salts thereof, and wherein:
n is 0 or 1;
R 6 is X—Y, wherein
X is a bond, O, S, N(R), C(O), N(R)C(O), C(O)N(R), or optionally substituted C 1 -C 3 alkyl, wherein
R is hydrogen or optionally substituted C 1 -C 6 alkyl, and
Y is optionally substituted C 1 -C 6 alkyl, cycloalkyl, C 3 -C 7 carbocyclyl, C 1 -C 6 alkoxy, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy or heteroaryl-S; and
R 5 , R 7 , and R 8 are each independently selected from hydrogen, halogen, hydroxyl, cyanyl, or N(R 1 )(R 2 ), or optionally substituted C 1 -C 6 alkyl, C 1 -C 6 alkynyl, C 1 -C 6 alkenyl, C 1 -C 6 alkoxy, C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy, or heteroaryl-S, in which
R 1 is hydrogen or optionally substituted C 1 -C 6 alkyl, and
R 2 is optionally substituted alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkylalkyl, aryl-CO, heteroaryl-CO, cycloalkyl-CO, or alkyl-CO.
15. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the compound of claim 14 .
16. A compound of Formula 4:
wherein a compound of Formula 4 includes isomers and pharmaceutically acceptable salts thereof, and wherein:
n is 0 or 1; and
R 3 is N(R)(R 9 ), N(R)C(O), C(O)N(R), or optionally substituted C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 6 -C 10 aryl-SO 2 , C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy, or heteroaryl-S, wherein
R is hydrogen or optionally substituted C 1 -C 6 alkyl, and
R 9 is optionally substituted C 3 -C 7 carbocyclyl, C 3 -C 7 carbocyclyloxy, C 4 -C 12 carbocyclylalkyl, C 4 -C 12 carbocyclylalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C 6 -C 10 aryl-S, C 7 -C 14 aralkoxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy, heterocyclylalkyl, heterocyclylalkoxy, C 6 -C 10 aryl-SO 2 , or heteroaryl-S.
17. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the compound of claim 16 .